Alain de Bruin

Prof. Dr. Alain de Bruin


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LKLindsey N. Kent
Lindsey N. Kent
SBSooin Bae
Sooin Bae
STShih-Yin Tsai
Shih-Yin Tsai
XTXing Tang
Xing Tang
ASArunima Srivastava
Arunima Srivastava
GLGustavo Leone
Gustavo Leone
Disruption of the retinoblastoma (RB) tumor suppressor pathway, either through genetic mutation of upstream regulatory components or mutation of RB1 itself, is believed to be a required event in cancer. However, genetic alterations in the RB-regulated E2F family of transcription factors are infrequent, casting doubt on a direct role for E2Fs in driving cancer. In this work, a mutation analysis of human cancer revealed subtle but impactful copy number gains in E2F1 and E2F3 in hepatocellular carcinoma (HCC). Using a series of loss- and gain-of-function alleles to dial E2F transcriptional output, we have shown that copy number gains in E2f1 or E2f3b resulted in dosage-dependent spontaneous HCC in mice without the involvement of additional organs. Conversely, germ-line loss of E2f1 or E2f3b, but not E2f3a, protected mice against HCC. Combinatorial mapping of chromatin occupancy and transcriptome profiling identified an E2F1- and E2F3B-driven transcriptional program that was associated with development and progression of HCC. These findings demonstrate a direct and cell-autonomous role for E2F activators in human cancer.

16 December 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BWBart Westendorp
Bart Westendorp
MMMichal Mokry
Michal Mokry
MKMarian J.A. Groot Koerkamp
Marian J.A. Groot Koerkamp
FHFrank C.P. Holstege
Frank C.P. Holstege
ECEdwin Cuppen
Edwin Cuppen
ABAlain de Bruin
Alain de Bruin
E2F transcription factors are known to be important for timely activation of G 1 /S and G 2 /M genes required for cell cycle progression, but transcriptional mechanisms for deactivation of cell cycle-regulated genes are unknown. Here, we show that E2F7 is highly expressed during mid to late S-phase, occupies promoters of G 1 /S-regulated genes and represses their transcription. ChIP-seq analysis revealed that E2F7 binds preferentially to genomic sites containing the TTCCCGCC motif, which closely resembles the E2F consensus site. We identified 89 target genes that carry E2F7 binding sites close to the transcriptional start site and that are directly repressed by short-term induction of E2F7. Most of these target genes are known to be activated by E2Fs and are involved in DNA replication, metabolism and DNA repair. Importantly, induction of E2F7 during G 0 -G 1 /S resulted in S-phase arrest and DNA damage, whereas expression of E2F7 during G 2 /M failed to disturb cell cycle progression. These findings provide strong evidence that E2F7 directly controls the downswing of oscillating G 1 /S genes during S-phase progression.

17 August 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
BWBart G M W Weijts
Bart G M W Weijts
WBWalbert J Bakker
Walbert J Bakker
PCPeter W A Cornelissen
Peter W A Cornelissen
KLKuo‐Hsuan Liang
Kuo‐Hsuan Liang
FSFrank H Schaftenaar
Frank H Schaftenaar
ABAlain de Bruin
Alain de Bruin
The E2F family of transcription factors plays an important role in controlling cell‐cycle progression. While this is their best‐known function, we report here novel functions for the newest members of the E2F family, E2F7 and E2F8 (E2F7/8). We show that simultaneous deletion of E2F7/8 in zebrafish and mice leads to severe vascular defects during embryonic development. Using a panel of transgenic zebrafish with fluorescent‐labelled blood vessels, we demonstrate that E2F7/8 are essential for proper formation of blood vessels. Despite their classification as transcriptional repressors, we provide evidence for a molecular mechanism through which E2F7/8 activate the transcription of the vascular endothelial growth factor A (VEGFA), a key factor in guiding angiogenesis. We show that E2F7/8 directly bind and stimulate the VEGFA promoter independent of canonical E2F binding elements. Instead, E2F7/8 form a transcriptional complex with the hypoxia inducible factor 1 (HIF1) to stimulate VEGFA promoter activity. These results uncover an unexpected link between E2F7/8 and the HIF1‐VEGFA pathway providing a molecular mechanism by which E2F7/8 control angiogenesis.

10 February 2016 in Veterinary Pathology
Verified
Journal Article
Closed access
PDF file
LHL. Harkema
L. Harkema
SYS. A. Youssef
S. A. Youssef
ABAlain de Bruin
Alain de Bruin
Progeroid mouse models display phenotypes in multiple organ systems that suggest premature aging and resemble features of natural aging of both mice and humans. The prospect of a significant increase in the global elderly population within the next decades has led to the emergence of “geroscience,” which aims at elucidating the molecular mechanisms involved in aging. Progeroid mouse models are frequently used in geroscience as they provide insight into the molecular mechanisms that are involved in the highly complex process of natural aging. This review provides an overview of the most commonly reported nonneoplastic macroscopic and microscopic pathologic findings in progeroid mouse models (eg, osteoporosis, osteoarthritis, degenerative joint disease, intervertebral disc degeneration, kyphosis, sarcopenia, cutaneous atrophy, wound healing, hair loss, alopecia, lymphoid atrophy, cataract, corneal endothelial dystrophy, retinal degenerative diseases, and vascular remodeling). Furthermore, several shortcomings in pathologic analysis and descriptions of these models are discussed. Progeroid mouse models are valuable models for aging, but thorough knowledge of both the mouse strain background and the progeria-related phenotype is required to guide interpretation and translation of the pathology data.

19 August 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
HGHilah Gal
Hilah Gal
MLMarina Lysenko
Marina Lysenko
SSSima Stroganov
Sima Stroganov
EVEzra Vadai
Ezra Vadai
SYSameh A Youssef
Sameh A Youssef
VKValery Krizhanovsky
Valery Krizhanovsky
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

25 July 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LKLindsey N. Kent
Lindsey N. Kent
JRJessica B. Rakijas
Jessica B. Rakijas
SPShusil Pandit
Shusil Pandit
Bart WestendorpBart Westendorp
Bart Westendorp
HCHui-Zi Chen
Hui-Zi Chen
GLGustavo Leone
Gustavo Leone
E2F-mediated transcriptional repression of cell cycle–dependent gene expression is critical for the control of cellular proliferation, survival, and development. E2F signaling also interacts with transcriptional programs that are downstream of genetic predictors for cancer development, including hepatocellular carcinoma (HCC). Here, we evaluated the function of the atypical repressor genes E2f7 and E2f8 in adult liver physiology. Using several loss-of-function alleles in mice, we determined that combined deletion of E2f7 and E2f8 in hepatocytes leads to HCC. Temporal-specific ablation strategies revealed that E2f8’s tumor suppressor role is critical during the first 2 weeks of life, which correspond to a highly proliferative stage of postnatal liver development. Disruption of E2F8’s DNA binding activity phenocopied the effects of an E2f8 null allele and led to HCC. Finally, a profile of chromatin occupancy and gene expression in young and tumor-bearing mice identified a set of shared targets for E2F7 and E2F8 whose increased expression during early postnatal liver development is associated with HCC progression in mice. Increased expression of E2F8-specific target genes was also observed in human liver biopsies from HCC patients compared to healthy patients. In summary, these studies suggest that E2F8-mediated transcriptional repression is a critical tumor suppressor mechanism during postnatal liver development.